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What\'s new?A woman with an unrecognized pre‐existing medullary thyroid carcinoma (MTC) who received a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) in a clinical trial provides a possibly unique case in the GLP‐1RA drug development literature.A lack of both serum calcitonin stimulation and functional glucagon‐like peptide‐1 receptor in this MTC was observed.

Introduction {#dme13437-sec-0005}
============

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), such as dulaglutide [1](#dme13437-bib-0001){ref-type="ref"}, exenatide extended‐release [2](#dme13437-bib-0002){ref-type="ref"} and liraglutide [3](#dme13437-bib-0003){ref-type="ref"}, are approved for improvement of glycaemic control in people with Type 2 diabetes mellitus. Although efficacious, concerns about the development of medullary thyroid carcinoma (MTC) have been raised based on studies in rodents [1](#dme13437-bib-0001){ref-type="ref"}, [2](#dme13437-bib-0002){ref-type="ref"}, [3](#dme13437-bib-0003){ref-type="ref"}, [4](#dme13437-bib-0004){ref-type="ref"}, hence, a boxed warning is included in the US package insert and GLP‐1RA product labelling. Medullary thyroid carcinoma accounts for 1--2% of primary thyroid malignancies and originates from parafollicular cells, also called C cells, which represent \~1% of cells in the human thyroid [5](#dme13437-bib-0005){ref-type="ref"}. Between 1983 and 2012, the mean annual age‐adjusted incidence of MTC rose significantly, from 0.14 to 0.21 per 100 000 people [6](#dme13437-bib-0006){ref-type="ref"}. Cases of MTC are mostly sporadic (80%), but \~20% may occur in hereditary form, typically associated with a mutation in the RET proto‐oncogene [5](#dme13437-bib-0005){ref-type="ref"}.

In rodents, activation of glucagon‐like peptide‐1 receptors (GLP‐1Rs) increases cyclic adenosine monophosphate in thyroid C cells, initiates the release of calcitonin, and eventually promotes C‐cell proliferation and tumours [7](#dme13437-bib-0007){ref-type="ref"}, [8](#dme13437-bib-0008){ref-type="ref"}, [9](#dme13437-bib-0009){ref-type="ref"}, [10](#dme13437-bib-0010){ref-type="ref"}, [11](#dme13437-bib-0011){ref-type="ref"}. Although calcitonin serves as an important biomarker for the presence of MTC [4](#dme13437-bib-0004){ref-type="ref"}, [12](#dme13437-bib-0012){ref-type="ref"}, [13](#dme13437-bib-0013){ref-type="ref"}, the GLP‐1RA‐mediated calcitonin increases noted in rodents have not been observed in studies in non‐human primates [11](#dme13437-bib-0011){ref-type="ref"}, [12](#dme13437-bib-0012){ref-type="ref"} or in humans with Type 2 diabetes [14](#dme13437-bib-0014){ref-type="ref"}, [15](#dme13437-bib-0015){ref-type="ref"}.

Dulaglutide is approved at once‐weekly doses of 0.75 and 1.5 mg (by subcutaneous injection) for treatment of Type 2 diabetes [1](#dme13437-bib-0001){ref-type="ref"}. Assessment of Weekly AdministRation of LY2189265 \[dulaglutide\] in Diabetes‐5 (AWARD‐5) was a phase II/III efficacy and safety study of dulaglutide compared with sitagliptin in people with Type 2 diabetes on metformin; participants were initially treated with dulaglutide 0.25, 0.50, 0.75, 1.00, 1.50, 2.00 or 3.00 mg during the dose‐finding portion of the study [16](#dme13437-bib-0016){ref-type="ref"}.

The present report describes an AWARD‐5 participant with pre‐existing MTC who exhibited no significant changes in serum calcitonin levels despite treatment with dulaglutide 2.0 mg for 6 months.

Case report {#dme13437-sec-0006}
===========

The participant was a 56‐year‐old white woman with no personal or family history of endocrine neoplasms. Relevant medical history included Type 2 diabetes, hypertension, oesophageal reflux, and obesity (BMI 30.6 kg/m^2^); she was a non‐smoker with no reported alcohol use.

She received once‐weekly dulaglutide 2.0 mg for Type 2 diabetes. Regular calcitonin monitoring was initiated after reports during the AWARD‐5 study of the potential effect of long‐acting GLP‐1RAs in animals [17](#dme13437-bib-0017){ref-type="ref"}. Table [1](#dme13437-tbl-0001){ref-type="table-wrap"} shows a timeline noting calcitonin measurements and other events. At the 6‐month discontinuation visit, the woman\'s fasting calcitonin level was elevated \[61.7 pg/ml (18.05 pmol/l); reference range 0.0--11.5 pg/ml (0.0--3.36 pmol/l); Table [1](#dme13437-tbl-0001){ref-type="table-wrap"}\].

###### 

Serum calcitonin by weeks following randomization into the AWARD‐5 study

                      AWARD‐5 treatment day --1[a](#dme13437-note-0002){ref-type="fn"}   AWARD‐5 discontinuation   Ultrasonography   Left hemithyroidectomy   Postoperative follow‐up visits   Completion thyroidectomy   Ultrasonography                                 
  ------------------- ------------------------------------------------------------------ ------------------------- ----------------- ------------------------ -------------------------------- -------------------------- ----------------- --------------- ------------- ---------------
  Week                0                                                                  23                        35                50                       51                               54                         62                65              76            278
  Date                17 December 2008                                                   4 June 2009               27 August 2009    11 December 2009         17 December 2009                 7 January 2010             5 March 2010      25 March 2010   9 June 2010   28 April 2014
  Calcitonin, pg/ml   91.5                                                               61.7                      82.8              ‐                        12.0                             14.0                       8.0               16.2            ‐             \<2.0

AWARD‐5, Assessment of Weekly AdministRation of LY2189265 \[dulaglutide\] in Diabetes Assessment‐5.

As per the AWARD‐5 protocol, the collection of a stored sample was drawn the day of randomization. Note: data presented in standard units. Système International (SI) units are pmol/l (conversion factor×0.2926).
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The woman\'s baseline calcitonin level was measured using stored serum and was elevated \[91.5 pg/ml (26.77 pmol/l); Table [1](#dme13437-tbl-0001){ref-type="table-wrap"}\]. She was not taking GLP‐1RA or dipeptidyl peptidase‐4 inhibitors at baseline. She was taking omeprazole, which may increase serum calcitonin, although not typically above 20 pg/ml (5.85 pmol/l) [18](#dme13437-bib-0018){ref-type="ref"}. Thyroid ultrasonography showed multiple small bilateral nodules, the largest 1.1 × 0.7 × 0.8 cm in the left lobe. Twelve weeks after dulaglutide was discontinued (week 23), serum calcitonin remained elevated and unchanged (Table [1](#dme13437-tbl-0001){ref-type="table-wrap"}). A fine~~‐~~needle aspiration of the large left lobe nodule was consistent with a follicular neoplasm.

Approximately 1 year after initiation of the study drug and 6 months after discontinuation, she underwent left hemithyroidectomy, and pathological examination confirmed MTC. Calcitonin level was reduced partially in the 3 months after surgery but remained elevated (Table [1](#dme13437-tbl-0001){ref-type="table-wrap"}). Approximately 5 months after surgery, ultrasonography of the right thyroid lobe nodules remained unchanged from presurgical assessments. A completion thyroidectomy was performed \~6 months after the first surgery. MTC was noted in the pathological assessment, 0.3 cm in greatest dimension, negative for lymphatic and vascular invasion, with two benign lymph nodes. Resection margins were free from malignancy. The last serum calcitonin level obtained, \~44 months after this second procedure, was \<2 pg/ml (0.59 pmol/l). An assay of excised normal thyroid tissue indicated that the woman was heterozygous positive for the RET V804M mutation, a common variant associated with hereditary MTC [5](#dme13437-bib-0005){ref-type="ref"}, [19](#dme13437-bib-0019){ref-type="ref"}, [20](#dme13437-bib-0020){ref-type="ref"}. Subsequently, immunohistochemistry staining was performed to assess the presence of GLP‐1R in her tumour tissue.

Details of the methodology are provided in the Supporting Information, File [S1](#dme13437-sup-0001){ref-type="supplementary-material"}. Results (Fig. [1](#dme13437-fig-0001){ref-type="fig"}) showed positive cytoplasmic staining for GLP‐1R in a few scattered cells in the MTC sample, while membranous GLP‐1R staining was not seen. Pancreas tissues from mice that express the human GLP‐1R from the murine *Glp‐1r* promoter and endogenous upstream regulatory elements [21](#dme13437-bib-0021){ref-type="ref"} were used to confirm the ability of the antibody to detect membranous GLP‐1R (consistent with a functional receptor). Further, HEK293 cells expressing the GLP‐1R showed positive signal, whereas none was observed in the parent HEK293 cells or Glp‐1r knockout tissues (data not shown).

![Immunohistochemistry of human glucagon‐like peptide‐1 receptor (GLP‐1R) knock‐in mouse pancreas (a) at control (40×) magnification, demonstrating membranous GLP‐1R detection in the central cells of the islet (consistent with β‐cell labelling). Haematoxylin and eosin‐stained sections of the patient medullary thyroid cancer (MTC) (b) at low (2.5×) magnification, demonstrating entire tumour nodule with compression of surrounding normal thyroid follicles and (c) and (d) at 20× illustrating both haematoxylin and eosin and immunohistochemistry.](DME-35-381-g001){#dme13437-fig-0001}

Discussion {#dme13437-sec-0007}
==========

Given a retrospective baseline serum value for calcitonin nearly nine times the upper limit of normal, and evidence of a germline RET proto‐oncogene mutation, MTC in this woman was considered to be pre‐existing to the short‐term GLP‐1RA exposure that began in December 2008. Beginning in April 2009, people with Type 2 diabetes in clinical trials involving long‐acting GLP‐1RAs were required to be screened for serum calcitonin to rule out C‐cell disease [17](#dme13437-bib-0017){ref-type="ref"}.

The membranous GLP‐1R immunohistochemistry signal in the control knock‐in mouse pancreas is consistent with published results [22](#dme13437-bib-0022){ref-type="ref"}, [23](#dme13437-bib-0023){ref-type="ref"}. Results from GLP‐1R immunohistochemistry of the woman\'s MTC sample showed a lack of cell surface GLP‐1R staining.

Broad conclusions are limited based on this report in one woman with MTC with a RET mutation (V804M) [5](#dme13437-bib-0005){ref-type="ref"}. This mutation is associated with a less aggressive course of MTC; therefore, generalization to others with MTC may not be appropriate. Additionally, the duration of GLP‐1RA treatment was only 23 weeks, and although no obvious change in serum calcitonin was observed, it may not be possible to conclude that longer‐term treatment would not have influenced tumour progression or serum calcitonin level.

The lack of calcitonin stimulation and absence of plasma membrane GLP‐1R in this case of MTC are reassuring; however, as screening for MTC is not routine before initiating GLP‐1RA treatment [4](#dme13437-bib-0004){ref-type="ref"}, this woman\'s experience may be similar to that in clinical practice. Whereas the incidence of clinical MTC is very low [5](#dme13437-bib-0005){ref-type="ref"}, the incidence of occult MTC is higher [24](#dme13437-bib-0024){ref-type="ref"}, [25](#dme13437-bib-0025){ref-type="ref"}, therefore, others with occult MTC are likely to be exposed to long‐acting GLP‐1RAs. Future investigations are needed to evaluate the role of GLP‐1RAs on the initiation and, perhaps more importantly, the natural history of C‐cell neoplasia in humans [26](#dme13437-bib-0026){ref-type="ref"}. The MTC Registry, established in 2010 to provide a source of data for the incidence and prevalence of MTC and GLP‐1RA exposure, may prove to be an investigational resource for subsequent research as additional such cohorts are identified [26](#dme13437-bib-0026){ref-type="ref"}.
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